|
METTL8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
9.20400422543821E-11 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
3.026400E-01 |
| Stage1-vs-Stage3 |
8.208200E-01 |
| Stage1-vs-Stage4 |
2.033600E-02 |
| Stage2-vs-Stage3 |
3.163600E-01 |
| Stage2-vs-Stage4 |
1.175990E-02 |
| Stage3-vs-Stage4 |
7.168200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.95410029771404E-10 |
| Normal-vs-Asian |
1.71418435002124E-12 |
| Caucasian-vs-AfricanAmerican |
9.266600E-01 |
| Caucasian-vs-Asian |
9.982400E-01 |
| AfricanAmerican-vs-Asian |
9.363800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.456800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.70374825358977E-12 |
| Normal-vs-Age(81-100Yrs) |
5.033000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.902800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.023400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.615800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.624000E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.925030E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.869600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.760800E-01 |
| Classical-VS-Follicular |
9.194600E-01 |
| Classical-VS-Other |
3.783600E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
5.690600E-01 |
| Tall-VS-Other |
7.810400E-01 |
| Tall-VS-Normal |
9.48420000312922E-08 |
| Follicular-VS-Other |
4.074600E-01 |
| Follicular-VS-Normal |
1.62492241884138E-12 |
| Other-VS-Normal |
2.42449999998673E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.084600E-03 |
|
|
